

**19-NOV-2017 6:10  
CANCER CONTROL ACCRUAL REPORT**

06:10 Sunday, November 19, 2017 1

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
			REGS.	LAST Month	LAST Month	LAST Month	LAST DAYS	LAST DAYS	
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1 Y 1	Recurrence Score testing	9383	663	264	90	0	0	BREAST
			9383	663	264	90	0	0	
	2 Y 2	Chemo and Endocrine Therapy	2547	230	99	36	2	0	
		3 Endocrine Therapy Alone	2536	232	100	38	2	0	
			5083	462	199	74	4	0	
S1207-Brst,Adj,Endocrine+/-Everolimus	1 Y 1	Blinded drug + Endocrine	705	202	92	47	17	5	BREAST
		2 Blinded drug + Endocrine	711	213	103	57	13	2	
			1416	415	195	104	30	7	
S1316-Compar. Effectiv. Trial for MBO	1 Y 1	Randomization Surgery	4	3	3	3	1	1	SURV
		2 Randomization Non-surgical M	3	3	3	2	2	0	
		3 Patient Choice Surgery	37	21	12	5	2	1	
		4 Patient Choice Non-surgical M	80	46	27	11	4	1	
			124	73	45	21	9	3	
S1400I-Non-Match: Nivo + Ipi vs Nivo	1 Y 1	Nivolumab + Ipilimumab	122	54	24	14	5	1	LUNG
		2 Nivolumab	123	54	23	13	5	1	
			245	108	47	27	10	2	
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	2 Y 2	FDA approved regimen	678	430	168	26	0	0	MELAN
		3 MK-3475 (Pembrolizumab)	667	409	157	27	0	0	
			1345	839	325	53	0	0	
S1415CD-TrACER CSF Standing Order Intervention for FN	1 Y 1	Site assigned to Cohort	348	338	153	61	18	10	CCD
		2 Site randomized: Control	218	218	148	69	23	8	
		3 SiteRand Int Risk: CSF	297	297	201	113	34	13	
		4 SiteRand Int Risk: No CSF	222	222	163	88	19	7	
			1085	1075	665	331	94	38	
S1417CD-Colorectal, Cost Cohort Study	1 Y 1	Observation	133	122	82	42	13	3	CCD
			133	122	82	42	13	3	
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1 Y 1	Tissue for PD-L1 testing	111	111	83	51	21	5	BREAST
			111	111	83	51	21	5	
	2 Y 2	Observation	50	50	43	26	13	2	
		3 MK-3475 (Pembrolizumab)	44	44	33	17	5	3	

**19-NOV-2017 6:10  
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
			REGS.	LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS	
			94	94	76	43	18	5	
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	1	Y 0	Screening	2	2	2	2	2	1 SURV
				2	2	2	2	2	1
	2	Y 1	Carvedilol	1	1	1	1	1	1
	3		Observation	1	1	1	1	1	1
				2	2	2	2	2	2
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y 1	TICE BCG	17	17	13	9	3	1 GU
	2		Tokyo-172 BCG	16	16	14	9	3	1
	3		Prime + Tokyo-172 BCG	18	18	16	11	6	2
				51	51	43	29	12	4
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0	Y 0	Pre-Registration	425	137	72	30	17	2 PREV
				425	137	72	30	17	2
	1	Y 1	Blinded drug	45	15	6	2	0	0
	2		Blinded drug	36	9	0	0	0	0
	3		Blinded drug	35	10	0	0	0	0
	4		Blinded drug	48	21	11	5	0	0
				164	55	17	7	0	0